cafepharma.com /2 weeks ago

Argenx

Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
cafepharma.com /1 month ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
webwire.com /3 days ago

Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis...

Read source
pharmexec.com /1 week ago

<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>

Read source
biopharmadive.com /1 month ago

Argenx falls as Sjögren’s setback offsets celiac drug progress

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

Read source
biopharmadive.com /1 week ago

Argenx to buy peptide platform in potentially billion-dollar deal

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-medi...

Read source
pharmexec.com /1 month ago

<![CDATA[Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engag...

Read source
seekingalpha.com /2 weeks ago

Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma - Slideshow

Read source
cafepharma.com /1 week ago

Averitas

Averitas Anonymous (not verified) Wed, 11/11/2026 - 21:36 field_thread_url https://cafepharma.com/boards/threads/averitas.667825/ board...

Read source
cafepharma.com /1 month ago

Averitas

Averitas Anonymous (not verified) Wed, 10/21/2026 - 13:15 field_thread_url https://cafepharma.com/boards/threads/averitas.667825/ board...

Read source
biopharmadive.com /1 week ago

Vir hepatitis D drug succeeds in first pivotal study

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage developmen...

Read source
cafepharma.com /6 days ago

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
biopharmadive.com /3 days ago

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx. 

Read source
seekingalpha.com /2 weeks ago

Arvinas outlines cash runway into the second half of 2028 while targeting multiple Phase I readouts through 2027

Read source
pharmexec.com /1 week ago

<![CDATA[Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.